BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24763611)

  • 1. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis.
    Chen D; Wei L; Yu J; Zhang L
    Clin Cancer Res; 2014 Jul; 20(13):3472-84. PubMed ID: 24763611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
    Dudgeon C; Peng R; Wang P; Sebastiani A; Yu J; Zhang L
    Oncogene; 2012 Nov; 31(46):4848-58. PubMed ID: 22286758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idelalisib induces PUMA-dependent apoptosis in colon cancer cells.
    Yang S; Zhu Z; Zhang X; Zhang N; Yao Z
    Oncotarget; 2017 Jan; 8(4):6102-6113. PubMed ID: 28008149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
    Zheng X; He K; Zhang L; Yu J
    Mol Cancer Ther; 2013 May; 12(5):777-86. PubMed ID: 23427294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aurora kinase inhibition induces PUMA via NF-κB to kill colon cancer cells.
    Sun J; Knickelbein K; He K; Chen D; Dudgeon C; Shu Y; Yu J; Zhang L
    Mol Cancer Ther; 2014 May; 13(5):1298-308. PubMed ID: 24563542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gilteritinib induces PUMA-dependent apoptotic cell death via AKT/GSK-3β/NF-κB pathway in colorectal cancer cells.
    Li L; Lin L; Li M; Li W
    J Cell Mol Med; 2020 Feb; 24(3):2308-2318. PubMed ID: 31881122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.
    Yang S; Zhang X; Qu H; Qu B; Yin X; Zhao H
    Cancer Gene Ther; 2020 May; 27(5):368-377. PubMed ID: 31182761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PUMA induction by FoxO3a mediates the anticancer activities of the broad-range kinase inhibitor UCN-01.
    Dudgeon C; Wang P; Sun X; Peng R; Sun Q; Yu J; Zhang L
    Mol Cancer Ther; 2010 Nov; 9(11):2893-902. PubMed ID: 20978166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis.
    Zhang L; Wang H; Li W; Zhong J; Yu R; Huang X; Wang H; Tan Z; Wang J; Zhang Y
    Oncotarget; 2017 Jan; 8(2):3289-3303. PubMed ID: 27924057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer.
    Yan J; Yang S; Tian H; Zhang Y; Zhao H
    Cell Death Dis; 2020 Nov; 11(11):943. PubMed ID: 33139695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
    Tan X; Zhang Z; Liu P; Yao H; Shen L; Tong JS
    Cell Death Dis; 2020 Dec; 11(12):1061. PubMed ID: 33311453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: In vitro and in vivo study.
    Wang YJ; Zhang YK; Zhang GN; Al Rihani SB; Wei MN; Gupta P; Zhang XY; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2017 Jun; 396():145-154. PubMed ID: 28302530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptosis induction and AKT/NF-κB inactivation are associated with regroafenib-inhibited tumor progression in non-small cell lung cancer in vitro and in vivo.
    Weng MC; Li MH; Chung JG; Liu YC; Wu JY; Hsu FT; Wang HE
    Biomed Pharmacother; 2019 Aug; 116():109032. PubMed ID: 31163381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
    Liu Q; Mier JW; Panka DJ
    Mol Cancer; 2011 Sep; 10():115. PubMed ID: 21929745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer.
    Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L
    Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab.
    Napolitano S; Martini G; Rinaldi B; Martinelli E; Donniacuo M; Berrino L; Vitagliano D; Morgillo F; Barra G; De Palma R; Merolla F; Ciardiello F; Troiani T
    Clin Cancer Res; 2015 Jul; 21(13):2975-83. PubMed ID: 25838391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The cytotoxic effects of regorafenib in combination with protein kinase D inhibition in human colorectal cancer cells.
    Wei N; Chu E; Wu SY; Wipf P; Schmitz JC
    Oncotarget; 2015 Mar; 6(7):4745-56. PubMed ID: 25544765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EZH2-mediated Puma gene repression regulates non-small cell lung cancer cell proliferation and cisplatin-induced apoptosis.
    Liu H; Li W; Yu X; Gao F; Duan Z; Ma X; Tan S; Yuan Y; Liu L; Wang J; Zhou X; Yang Y
    Oncotarget; 2016 Aug; 7(35):56338-56354. PubMed ID: 27472460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.